statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today...

Glaukos Announces the Release of its 2023 Sustainability Report

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans...

Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1

Glaukos Co. (NYSE:GKOS - Get Free Report) CFO Alex R. Thurman sold 434 shares of the stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $95.33...

Alex R. Thurman Sells 434 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Corporation's ( NYSE:GKOS ) price-to-sales (or "P/S") ratio of 14.8x might make it look like a strong sell...

Glaukos Corporation (NYSE:GKOS) Not Lagging Industry On Growth Or Pricing

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Glaukos receives permanent J-code for iDose TR

Glaukos Receives Permanent J-code for iDose TR (travoprost intracameral implant)

Glaukos (NYSE:GKOS - Get Free Report)s stock had its "buy" rating reissued by analysts at Stifel Nicolaus in a note issued to investors on Wednesday, Benzinga reports. They presently have a...

Glaukos (NYSE:GKOS) Stock Rating Reaffirmed by Stifel Nicolaus

This is a signal that GKOS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Glaukos (GKOS, $93.1) RSI Indicator left the overbought zone on April 01, 2024

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases...

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Shares of Glaukos Co. (NYSE:GKOS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the company, Marketbeat Ratings...

Glaukos Co. (NYSE:GKOS) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Volume	288,509.00
52-Wk High	$103.66
52-Wk Low	$45.38

GKOS Glaukos Corporation

About

Feed

News

Sentiment

Earnings

Fundamentals